flarex
immedica pharma ab - fluorometolonas - akių lašai (suspensija) - 1 mg/ml - fluorometholone
tobrex
lex ano, uab - tobramicinas - akių tepalas - 3 mg/g - tobramycin
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
ambrisentan teva
teva b.v. - ambrisentanas - plėvele dengtos tabletės - 5 mg - ambrisentan
finadyne vet. 50 mg/ml užpilamasis tirpalas galvijams
intervet international b.v. (nyderlandai) - užpilamasis tirpalas - 1 ml yra: fluniksino - 50,0 mg (atitinka 83 mg fluniksino meglumino). - karščiavimui, susijusiam su galvijų kvėpavimo sistemos ligomis, mažinti.. karščiavimui, susijusiam su ūminiu mastitu, mažinti.skausmui ir šlubavimui, susijusiems su tarpupirščių flegmona, tarpupirščių dermatitu ir pirštų dermatitu, mažinti.
ultarcorlene
agepha pharma s.r.o - prednizolono pivalatas - akių tepalas - 5 mg/g - prednisolone
bitimeco
zakłady farmaceutyczne polpharma s.a. - bimatoprostas/timololis - akių lašai (tirpalas) - 0,3 mg/5 mg/ml - timolol, combinations
stromease 25 mg/ml, akių lašai (tirpalas) šunims ir katėms
domes pharma sc (prancūzija) - akių lašai, tirpalas - kiekviename ml yra: veikliosios (-iųjų) medžiagos (-ų): acetilcisteino 25,00 mg. - ragenos opų palaikomasis gydymas.
tobrex
lex ano, uab - tobramicinas - akių tepalas - 3 mg/g - tobramycin
terbinafine bijon
bijon medica, uab - terbinafinas - tabletės - 250 mg - terbinafine